化学
小分子
激酶
PI3K/AKT/mTOR通路
药物发现
铅化合物
甲酰胺
结构-活动关系
立体化学
蛋白激酶B
药理学
作者
Deborah S. Mortensen,Sophie M. Perrin-Ninkovic,Roy Harris,Branden G.S. Lee,Graziella I. Shevlin,Matthew Hickman,Gody Khambatta,Rene Bissonette,Kimberly E. Fultz,Sabita Sankar
标识
DOI:10.1016/j.bmcl.2011.09.035
摘要
We report here the discovery of a novel series of selective mTOR kinase inhibitors. A series of imidazo[4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compounds with excellent mTOR potency and exquisite kinase selectivity. Potent compounds from this series show >1000-fold selectivity over the related PI3Kα lipid kinase. Further, compounds such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473).
科研通智能强力驱动
Strongly Powered by AbleSci AI